Money
Briefing: Big drugmakers saved at least $5bn on US taxes shifting income overseas
Strategic angle: New disclosures show how pharma groups reduced federal levies last year by assigning profits to low-tax jurisdictions.
editorial-staff
1 min read
Updated 22 days ago
Pharmaceutical companies have reportedly saved $5 billion in federal taxes by shifting income to low-tax jurisdictions. This strategy has become increasingly common among large drugmakers.
The practice of income shifting allows these companies to minimize their tax liabilities, impacting the overall tax revenue collected by the U.S. government.
As pharmaceutical firms continue to optimize their tax strategies, the implications for federal tax policy and regulatory scrutiny may increase, necessitating a closer examination of their operational frameworks.